BioMarin Pharmaceuticals BMRN Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxAssetsNet.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's deferred tax assets?
- BioMarin Pharmaceuticals (BMRN) reported deferred tax assets of $1.5B in Q1 2026.
- How has BioMarin Pharmaceuticals's deferred tax assets changed year-over-year?
- BioMarin Pharmaceuticals's deferred tax assets increased by 2.7% year-over-year, from $1.46B to $1.5B.
- What is the long-term trend for BioMarin Pharmaceuticals's deferred tax assets?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's deferred tax assets has grown at a 1.0% compound annual growth rate (CAGR), from $1.43B to $1.51B.
- What does deferred tax assets mean?
- The value of future tax savings that the company expects to realize.
- How do you interpret deferred tax assets?
- An increase may indicate accumulated tax losses or R&D credits, while a decrease suggests the company is utilizing these assets to offset taxable income.
- How does deferred tax assets compare across companies?
- Common in high-growth biotech companies with historical R&D-heavy investment cycles.